Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!Blood reviews · 2018
   Review
2. Developing T-cell therapies for lymphoma without receptor engineering.Blood advances · 2017
   Review
3. Developing T-cell therapies for lymphoma without receptor engineering.Hematology. American Society of Hematology. Education Program · 2017
   Review
4. Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature.Experimental hematology & oncology · 2017
   Review

Corrections and comments

• Comment on
  Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation.2016

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as